Skip to main
BDSX

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix is a company with a competitive position and potential for growth and profitability. Despite its current negative cash flow, the company is focused on hiring, increasing sales, and conserving capital while potentially raising additional capital in the next 12 months. With a potential first-mover advantage and a potential market value of $27 billion annually, the company is working towards achieving profitability and mitigating challenges such as potential competition and changes in reimbursement rates. Additionally, Biodesix is actively pursuing new products and partnerships to drive its growth, but its financial stability may be impacted by decisions from Medicare and commercial payers.

Bears say

Biodesix is a diagnostic solutions company with a single operating segment focused on providing diagnostic testing services and companion diagnostics to biopharmaceutical companies. However, despite strong growth in diagnostic testing revenue, the company's financials remain negative, and there are significant risks to achieving the projected price target of $27, including lower-than-expected revenue growth, competition from potential future market entrants, and the need to maintain favorable reimbursement. Additionally, the company's pipeline tests are dependent on successful clinical evidence generation, and any unfavorable data outcomes could negatively impact future growth prospects.

Biodesix (BDSX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.